KH-617 is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KH-617’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KH-617 overview

KH-617 is under development for the treatment of recurrent glioblastoma multiforme, solid tumor and brain metastases. It is administered through intravenous route.

Chengdu Kanghong Pharmaceuticals Group overview

Chengdu Kanghong Pharmaceuticals Group (Kanghong Pharmaceuticals) focuses on the development, manufacturing and marketing of Chinese medicines, chemical drugs, and biological products. It offers products for the treatment of medical conditions related to the central nervous system, ophthalmology, digestive system, gastrointestinal, and diabetes among others. Kanghong Pharmaceutical products include Lumitin, Bosiqing, Bolexin, Danshu, Xinluona, Yiqing, Keluoxin, Yitanning, and Xuanmaiganju. The company offers its products in the form of dispersible tablets, ophthalmic injections, oral drugs, detoxification drugs, and antiviral medicines. Kanghong Pharmaceuticals is headquartered in Chengdu, Sichuan, China.

For a complete picture of KH-617’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.